Lindus Health Reaches $55M Series B to Accelerate Clinical Trials

Lindus Health, a London and New York-based startup, is revolutionizing the clinical trials industry with its anti-CRO approach, which provides faster, more cost-effective, and reliable clinical trials using innovative technology solutions. Founded by Michael Young, Meri Beckwith, and Nik Haldimann, the company aims to overhaul traditional CRO models that often suffer from delays and inefficiency by employing fixed-price quotes per study, milestone-based payment systems, and leveraging insights from over 40 million Electronic Health Records. Lindus Health's technological edge is driven by its AI-based clinical trial software platform, Citrus, which facilitates streamlined patient recruitment and dynamic trial designs. The company recently completed its $55 million Series B funding, led by Balderton Capital and supported by Seedcamp, Visionaries Club, Creandum, and Firstminute. Lindus Health has conducted 42 clinical trials to date, impacting areas such as psychiatry and diagnostics, and enrolled over 36,000 participants worldwide. This funding injection will aid in further developing their AI technology and eClinical platform to enhance study design and data monitoring while hiring skilled personnel in clinical operations and product development.